Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amazon Hurricane Heading Towards Indian Pharma?

Executive Summary

Think Amazon, think disruption, and that’s exactly what could be in store if the online retail juggernaut goes through with its rumored plans to invest in MedPlus, India’s second largest retail pharmacy chain. A deal could also have ramifications for private equity/venture capital activity in the Indian pharmacy space, say some experts.

You may also be interested in...



India Pharma In 2019: Buy, Build And Beware (Patient Power And Amazon)

2019 promises to be action-packed for Indian firms as they stay hungry for M&A and on course to transition to a more innovation-led play. But election year surprises in India, rising patient awareness, and the entry of non-traditional players like Amazon could well up the variable quotient for pharma, industry pundits tell Scrip.

Bumpy Ride Awaits Indian Firms In 2018 (And Then There’s Amazon)

2018 may not be smooth sailing for Indian firms, going by the predictions of top industry pundits. Possible upheavals on the domestic market, dynamics that demand a hawk eye on expenses and gains but also pressures as a result of FDA reforms suggest that a relatively tough year may be in store.

Remdesivir India Sub-Licensing: Gilead Indicates Conditional Position For Subcontracting

Gilead clarifies position on Cipla’s sub-licensing effort for remdesivir, the investigational antiviral in the global spotlight as a potential treatment for COVID-19.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132087

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel